Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113.5 AUD | +1.27% | +5.89% | +18.46% |
Apr. 02 | Pro Medicus Limited authorizes a Buyback Plan. | CI |
Apr. 01 | Pro Medicus Limited announces an Equity Buyback for 10,442,488 shares, representing 10% of its issued share capital. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 147.87 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.46% | 7.66B | C- | ||
+21.71% | 3.85B | B- | ||
-15.32% | 3.14B | C- | ||
-19.00% | 1.35B | B | ||
-31.01% | 1.18B | - | ||
+5.03% | 934M | C | ||
-34.81% | 911M | - | ||
-23.74% | 840M | - | C+ | |
-15.18% | 726M | - | ||
-12.45% | 597M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PME Stock
- Ratings Pro Medicus Limited